pharma · Primary Brain Tumor · Hepatocellular Carcinoma
Guerbet
Guerbet is a pharma organization headquartered in VILLEPINTE, FR. Primary therapeutic focus areas include Primary Brain Tumor, Hepatocellular Carcinoma, Motor Function. NovaPharmaNews links 4 clinical program(s), 0 drug
VILLEPINTE, FR HQ
1926 Founded
2,465 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- VILLEPINTE, FR
- Founded
- 1926
- Employees
- 2,465
- Programs
- 4
- Drugs
- 5
- Patents
- 0
GDX-102/GDX-44-017
Phase 3 · small molecule · Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar), peripheral or abdominal/renal arteries
GDX-102/GDX-44-017 for Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar), peripheral or abdominal/renal arteries is a Phase 3 program (small_molecule) at Guerbet with 1 ClinicalTrials.gov record(s).
Internal code GDX-102/GDX-44-017
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Guerbet
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar), peripheral or abdominal/renal arteries
- Status
- active
- Trials
- 1